|
|
Article: Texas Bio Dissolves ICOS Venture, Regains Full Rights To Sitaxsentan.
- Article from:
- BIOWORLD Today
- Article date:
- November 4, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
It seems Texas Biotechnology Corp. is sticking to its guns.
Just two months after reporting plans to reacquire full ownership rights to a late-stage cardiovascular drug developed in a limited partnership, the Houston-based company has decided to acquire all assets of the joint venture. (See BioWorld Today, Feb. 3, 2003.)
Texas Biotechnology will pay $10 million to ICOS Corp. in return for the latter's 50 percent interest in ICOS-Texas Biotechnology LP, effectively returning to the former full ownership rights to the endothelin receptor antagonist program. Sitaxsentan, a Phase III compound designed to treat pulmonary arterial ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|